The Journal of rheumatology · 2026
Epidemiological Characteristics of Psoriatic Disease in Peru From 2016 to 2023.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rodríguez-Zúñiga Milton, Torres-Panduro Natalie, Jumpa-Armas David
Аннотация
OBJECTIVE: This study aims to estimate the incidence rate (IR) of psoriatic disease (psoriasis [PsO] and psoriatic arthritis [PsA]), including crude and age- and sex-standardized rates, in the Peruvian healthcare system.
METHODS: A secondary data analysis was conducted using nationwide records (2016-2023) from the National Superintendence of Health (SUSALUD), encompassing both public and private sectors. IRs were calculated per 100,000 person-years (PY).
RESULTS: Among 195,866 PsO cases and 6786 PsA cases, overall IRs were 102.99 (95% CI 102.54-103.45) and 3.57 (95% CI 3.48-3.65) per 100,000 PY, respectively. Both conditions showed increasing trends from 2016 to 2023. PsO incidence peaked in adults aged ≥ 65 years (IR 300.46 per 100,000 PY) and was higher in male than female individuals (IR 130.04 vs 76.94 per 100,000 PY). Conversely, PsA demonstrated a bimodal age distribution, with an early peak at 40-44 years and a later, higher peak at 60-64 years, while maintaining a balanced sex distribution. Regional disparities were prominent; Lima-Callao reported the highest rates, whereas the Macro Central region had the lowest.
CONCLUSION: PsO and PsA IRs are rising in Peru, with notable demographic and regional variation. The lower incidence in the Andean macroregions may reflect a combination of healthcare access barriers and a protective genetic profile associated with Native American ancestry. These findings underscore the need for improved public health policies to address the growing demand for psoriatic disease care.
METHODS: A secondary data analysis was conducted using nationwide records (2016-2023) from the National Superintendence of Health (SUSALUD), encompassing both public and private sectors. IRs were calculated per 100,000 person-years (PY).
RESULTS: Among 195,866 PsO cases and 6786 PsA cases, overall IRs were 102.99 (95% CI 102.54-103.45) and 3.57 (95% CI 3.48-3.65) per 100,000 PY, respectively. Both conditions showed increasing trends from 2016 to 2023. PsO incidence peaked in adults aged ≥ 65 years (IR 300.46 per 100,000 PY) and was higher in male than female individuals (IR 130.04 vs 76.94 per 100,000 PY). Conversely, PsA demonstrated a bimodal age distribution, with an early peak at 40-44 years and a later, higher peak at 60-64 years, while maintaining a balanced sex distribution. Regional disparities were prominent; Lima-Callao reported the highest rates, whereas the Macro Central region had the lowest.
CONCLUSION: PsO and PsA IRs are rising in Peru, with notable demographic and regional variation. The lower incidence in the Andean macroregions may reflect a combination of healthcare access barriers and a protective genetic profile associated with Native American ancestry. These findings underscore the need for improved public health policies to address the growing demand for psoriatic disease care.